How I Treat Primary Immune Deficiencies with Hematopoietic Stem Cell Transplantation

다국어 초록 (Multilingual Abstract)

Primary immune deficiencies (PID), or more recently, inborn errors of immunity (IEI), resulting from genetic defects of the immune system may present with increased sus-ceptibility to infections, persistent inflammation, and autoimmunity. With recent in-troduction of next generation sequencing, the number of IEIs increases rapidly, reaching to 484 in 2022. Hematopoietic stem cell transplantation (HSCT) has been used over decades as a mainstay of specific treatment modality, while gene therapy and pharmacologic approach have been attempted with promising results in some PID in recent years. The survival following allogeneic HSCT for PID is now generally ＞80%. The indication and timing of transplant must be individualized not only on the basis of the specific PID but also on the characteristics of the individual patient. For the successful transplant outcome, the choice of donor and the optimal pretrans-plant conditioning regimen is important. This article will discuss current status and recommendations from specialists in HSCT for some representative PID, including severe combined immunodeficiency (SCID), CD40 ligand or CD40 deficiency, Wiskott-Aldrich syndrome, hemophagocytic lymphohistiocytosis, and chronic gran-ulomatous disease, along with our personal experience of PID treatment in Korea.

참고문헌 (Reference)

1 Booth C, "X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency : a multicenter study on the manifestations, management and outcome of the disease" 117 : 53-62, 2011

2 Speckmann C, "X-linked inhibitor of apoptosis(XIAP)deficiency : the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis" 149 : 133-141, 2013

3 Jo EK, "X-linked hyper-IgM syndrome associated with Cryptosporidium parvum and Cryptococcus neoformans infections : the first case with molecular diagnosis in Korea" 17 : 116-120, 2002

4 Marciano BE, "X-linked carriers of chronic granulomatous disease : illness, lyonization, and stability" 141 : 365-371, 2018

5 조은경 ; Kumaki Satoru ; Du Wei ; Tsuchiya Shigeru ; Kanegane Hirokazu ; 송창화 ; Noh Ha Young ; Kim Young Ok ; Kim So Yeon ; Chung Hae Yul ; 김윤하 ; 국훈, "X-linked Severe Combined Immunodeficiency Syndrome: The First Korean Case with gamma c Chain Gene Mutation and Subsequent Genetic Counseling" 대한의학회 19 (19): 123-126, 2004

6 Slatter MA, "Treosulfan-based conditioning for inborn errors of immunity" 12 : 1-19, 2021

7 Morillo-Gutierrez B, "Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease : a multicenter experience" 128 : 440-448, 2016

8 Hershfield MS, "Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase" 316 : 589-596, 1987

9 Pai SY, "Transplantation outcomes for severe combined immunodeficiency, 2000-2009" 371 : 434-446, 2014

10 Hartz B, "The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis" 127 : 3281-3290, 2016

11 Blaese RM, "T lymphocyte-directed gene therapy for ADA-SCID : initial trial results after 4 years" 270 : 475-480, 1995

12 Son Sohee ; 강지만 ; Hahn Younsoo ; 안강모 ; 김예진, "Systematic review of literature and analysis of big data from the National Health Insurance System on primary immunodeficiencies in Korea" 대한소아청소년과학회 64 (64): 141-148, 2021

13 Marsh RA, "Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1" 20 : 1641-1645, 2014

14 Bousfiha AA, "Primary immunodeficiency diseases worldwide : more common than generally thought" 33 : 1-7, 2013

15 Meyts I, "Primary immunodeficiencies : a decade of progress and a promising future" 11 : 625753-, 2021

16 임정우 ; 김경효 ; 김동수 ; 김봉성 ; Jung Soo Kim ; Chang-HwiKim ; 김황민 ; 박희주 ; Ki Soo Pai ; 손병관 ; Kyung-Sue Shin ; Moo Young Oh ; 우영종 ; 유영 ; 이건수 ; 이경일 ; 이종국 ; 이준성 ; Eun Hee Chung ; 최은화 ; 한윤수 ; Hyun Young Park ; 김중곤, "Prevalence of Primary Immunodeficiency in Korea" 대한의학회 27 (27): 788-793, 2012

17 Marsh RA, "Practice pattern changes and improvements in hematopoietic cell transplantation for primary immunodeficiencies" 142 : 2004-2007, 2018

18 Canna SW, "Pediatric hemophagocytic lymphohistiocytosis" 135 : 1332-1343, 2020

19 King JR, "Newborn screening for primary immunodeficiency diseases : history, current and future practice" 38 : 56-66, 2018

20 Elfeky R, "New graft manipulation strategies improve the outcome of mismatched stem cell transplantation in children with primary immunodeficiencies" 144 : 280-293, 2019

21 de la Morena MT, "Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation" 139 : 1282-1292, 2017

22 Gennery AR, "Long term outcome and immune function after hematopoietic stem cell transplantation for primary immunodeficiency" 7 : 381-, 2019

23 Hacein-Bey-Abina S, "Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1" 118 : 3132-3142, 2008

24 Naik S, "Incorporation of thiotepa in a reduced intensity conditioning regimen may improve engraftment after transplant for HLH" 188 : e84-e87, 2020

25 Gatti RA, "Immunological reconstitution of sex-linked lymphopenic immunological deficiency" 2 : 1366-1369, 1968

26 Choi SH, "Immunohematologic reconstitution after allogeneic bone marrow transplantation in a patient with Wiskott-Aldrich syndrome" 1 : 65-72, 1997

27 Notarangelo LD, "Human inborn errors of immunity : an expanding universe" 5 : eabb1662-, 2020

28 Tangye SG, "Human inborn errors of immunity : 2022 update on the classification from the International Union of Immunological Societies Expert Committee" 1-35, 2022

29 Tangye SG, "Human inborn errors of immunity : 2019 update on the classification from the International Union of Immunological Societies Expert Committee" 40 : 24-64, 2020

30 Boushfiha A, "Human inborn errors of immunity : 2019 update of the IUIS phenotypical classification" 40 : 66-81, 2020

31 Rivers E, "How I manage patients with Wiskott Aldrich syndrome" 185 : 647-655, 2019

32 Castagnoli R, "Hematopoietic stem cell transplantation in primary immunodeficiency diseases : current status and future perspectives" 7 : 295-, 2019

33 Ono S, "Hematopoietic stem cell transplantation for XIAP deficiency in Japan" 37 : 85-91, 2017

34 Ferrua F, "Hematopoietic stem cell transplantation for CD40 ligand deficiency : results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study" 143 : 2238-2253, 2019

35 Lankester AC, "Hematopoietic cell transplantation in severe combined immunodeficiency : the SCETIDE 2006–2014 European cohort" 149 : 1744-1754, 2022

36 Slatter MA, "Hematopoietic cell transplantation in primary immunodeficiency – conventional and emerging indications" 14 : 103-114, 2018

37 Chiesa R, "Hematopoietic cell transplantation in chronic granulomatous disease : a study of 712children and adults" 136 : 1201-1211, 2020

38 Neven B, "Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for primary immunodeficiencies and inherited disorders in children" 25 : 1363-1373, 2019

39 Quinn, J, "Growth in diagnosis and treatment of primary immunodeficiency within the global Jeffrey Modell Centers Network" 18 : 19-, 2022

40 Fischer A, "Gene therapy for severe combined immunodeficiencies and beyond" 217 : e20190607-, 2020

41 Braun CJ, "Gene therapy for Wiskott-Aldrich syndrome-long-term efficacy and genotoxicity" 6 : 227ra33-, 2014

42 Burroughs LM, "Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome : a PIDTC report" 135 : 2094-2105, 2020

43 Rao K, "Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen" 138 : 1152-1160, 2016

44 Lankester AC, "EBMT/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity" 56 : 2052-2062, 2021

45 Nishimura A, "Conditioning regimens for inborn errors of immunity : current perspectives and future strategies" 116 : 7-15, 2022

46 Marsh RA, "Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders" 149 : 1097-1104, 2022

47 Touzot F, "CD45RA depletion in HLA-mismatched allogeneic hematopoietic stem cell transplantation for primary combined immunodeficiency : a preliminary study" 135 : 1303-1309, 2015

48 Fischer A, "Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies" 140 : 1388-1393, 2017

49 Bartelink IH, "Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults : a multicentre, retrospective cohort analysis" 3 : e526-e536, 2016

50 Marsh RA, "Allogeneic hematopoietic cell transplantation for XIAP deficiency : an international survey reveals poor outcomes" 121 : 877-883, 2013

51 Bruton OC, "Agammaglobulinemia" 9 : 722-728, 1952

52 Seligmann M, "A proposed classification of primary immunologic deficiencies" 45 : 817-825, 1968

53 Porteus MH, "A new class of medicines through DNA editing" 380 : 947-959, 2019